In financial accounting, a balance sheet is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity.
Bio-Gene Technology Limited Balance Sheet Statement - Assets
As of 30 Jun 2026, The total current assets of Bio-Gene Technology Limited (ASX:BGT) was around $2,472,669 which consisted of $1,939,590 of Cash, no Inventory and $407,639 of Net receivables. Current assets represent all the assets of a company that are expected to be conveniently sold, consumed, used, or exhausted through standard business operations within one year.
All amounts in AUD
The latest balance sheet of Bio-Gene Technology Limited also showed $8,291 of Property Plant Equipment and no Good will. Also there were $129,299 of Intangible assets and no Other assets. The total assets including current and Intangibles/Deferred Long Term Asset Charges were $2,610,259.
Bio-Gene Technology Limited Balance Sheet Statement - Liabilities
BGT's latest annual results shows the balance sheet has $223,544 of Accounts Payable. Also there were no Short/Long term debt, no Long term debt, no Other Current liabilities and $517,429 of Total Current Liabilities. Current liabilities are a company's short-term financial obligations that are due within one year or within a normal operating cycle.
As per the 30 Jun 2026's annual report of Bio-Gene Technology Limited, the total liabilities were $519,764.
BGT Balance Sheet Statement - Stock Holder Equity
Stockholders' equity, also referred to as shareholders' equity, is the remaining amount of assets available to shareholders after all liabilities have been paid. It is calculated either as a firm's total assets less its total liabilities or alternatively as the sum of share capital and retained earnings less treasury shares. Stockholders' equity might include common stock, paid-in capital, retained earnings and treasury stock.
The latest Balance sheet of Bio-Gene Technology Limited showed the total stock holder equity was $2,090,495 which consisted of $25,714,440 of Common stocks, $-24,199,413 of Retained earnings and no Other stock holder equity.
BGT Balance Sheet Statement History
Following table shows the history of balance sheet for Bio-Gene Technology Limited (BGT).
| 30 Jun 2026 | 30 Jun 2025 | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2022 | |
|---|---|---|---|---|---|
| Cash | 1,939,590 | 1,138,338 | 2,209,558 | 2,990,527 | - |
| Net Receivables | 407,639 | 472,424 | 523,958 | 445,550 | - |
| Inventory | - | - | - | - | - |
| Total Current Assets | 2,472,669 | 1,970,406 | 2,937,395 | 3,580,466 | - |
| Property Plant Equipment | 8,291 | 13,351 | 19,010 | 14,639 | - |
| Good Will | - | - | - | - | - |
| Intangible Assets | 129,299 | 166,242 | 203,185 | 240,128 | - |
| Other Assets | - | - | - | - | - |
| Deferred Long Term Asset Charges | - | - | - | - | - |
| Total Assets | 2,610,259 | 2,149,999 | 3,159,590 | 3,835,233 | - |
| Accounts Payable | 223,544 | 83,001 | 47,238 | 118,708 | - |
| Short/Long Term Debt | - | - | - | - | - |
| Other Current Liabilities | - | 51,209 | - | - | 75,000 |
| Long Term Debt | - | - | - | - | - |
| Other Liabilities | - | - | - | - | - |
| Total Current Liabilities | 517,429 | 510,131 | 345,925 | 573,873 | - |
| Total Liabilities | 519,764 | 522,983 | 368,446 | 613,884 | - |
| Common Stock | 25,714,440 | 22,944,866 | 21,524,527 | 19,545,553 | - |
| Retained Earnings | -24,199,413 | -22,029,940 | -19,640,419 | -17,432,318 | - |
| Treasury Stock | - | - | - | - | - |
| Other Stockholder Equity | - | - | - | - | - |
| Total Stockholder Equity | 2,090,495 | 1,627,016 | 2,791,144 | 3,221,349 | - |
| Net Tangible Assets | 1,961,196 | 1,460,774 | 2,587,959 | 2,981,221 | - |
Bio-Gene Technology Limited (ASX:BGT) Balance Sheet Statement FAQ
1. How much Cash Bio-Gene Technology Limited has on their balance sheet?
As of 30 Jun 2026, Bio-Gene Technology Limited (ASX:BGT) has $1,939,590 of Cash.
2. What's the long term debt of Bio-Gene Technology Limited?
As per the latest Balance sheet of Bio-Gene Technology Limited (ASX:BGT), it has no Long term debt.
3. How much share holder equity does Bio-Gene Technology Limited has?
The Bio-Gene Technology Limited (ASX:BGT)'s balance sheet shows that it has $2,090,495 of Total stock holder equity.